Table 3.

Tyrosine kinase and immune checkpoint inhibitors studied in ATC.

TKI or ICI	Targeted Alteration
Recently approved drugs in ATC
Dabrafenib + trametinib (150 mg twice daily + 2 mg once daily)	BRAF + MEK
Lenvatinib [24 mg daily]	VEGFR, FGFR, PDGFR-α, RET, c-kit, KIF5B-RET, CCDC6-RET, NcoA4-RET rearrangement
Drugs studied in ATC
Pembrolizumab	PD-1
Nivolumab	PD-1
Spartalizumab	PD-1
Durvalumab	PD-L1
Tremelimumab	CTLA-4
Sorafenib	VEGFR, PDGFR-β, c-kit, RAF, RET, FLT3
Sunitinib	VEGFR, PDGFR, RET, c-kit, FLT3
Vemurafenib	BRAF
Crizotinib	ALK, MET, ROS1
Everolimus	mTOR, PI3K
Pazopanib	VEGFR, FGFR, PDGFR, c-kit
Imatinib	Bcr-Abl, PDGFR, c-kit
Gefitinib	EGFR

ATC, anaplastic thyroid cancer; TKI, tyrosine kinase inhibitors; ICI, immune checkpoint inhibitors.